La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
EQL Pharma Gestione
Gestione criteri di controllo 2/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Axel Schorling
Amministratore delegato
n/a
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | 2yrs |
| Proprietà del CEO | 1.1% |
| Durata media del management | 2yrs |
| Durata media del Consiglio di amministrazione | 5.3yrs |
Aggiornamenti recenti sulla gestione
Recent updates
EQL Pharma's (STO:EQL) Shareholders Have More To Worry About Than Only Soft Earnings
Aug 22
Here's Why EQL Pharma (STO:EQL) Has A Meaningful Debt Burden
Aug 12EQL Pharma AB (publ)'s (NGM:EQL) P/E Is Still On The Mark Following 30% Share Price Bounce
Jun 13EQL Pharma (NGM:EQL) Is Doing The Right Things To Multiply Its Share Price
May 14EQL Pharma's (NGM:EQL) Weak Earnings May Only Reveal A Part Of The Whole Picture
Feb 21The Trend Of High Returns At EQL Pharma (NGM:EQL) Has Us Very Interested
Jun 28With EPS Growth And More, EQL Pharma (NGM:EQL) Makes An Interesting Case
Apr 28EQL Pharma AB (publ)'s (NGM:EQL) 26% Jump Shows Its Popularity With Investors
Feb 24EQL Pharma (NGM:EQL) Is Achieving High Returns On Its Capital
Dec 19Does EQL Pharma (NGM:EQL) Deserve A Spot On Your Watchlist?
Jun 29Is EQL Pharma (NGM:EQL) Using Too Much Debt?
Apr 29We Think EQL Pharma AB (publ)'s (NGM:EQL) CEO Compensation Looks Fair
Aug 10EQL Pharma (NGM:EQL) Hasn't Managed To Accelerate Its Returns
Jun 07If You Like EPS Growth Then Check Out EQL Pharma (NGM:EQL) Before It's Too Late
Apr 16How Many EQL Pharma AB (publ) (NGM:EQL) Shares Have Insiders Sold, In The Last Year?
Mar 11Are EQL Pharma's (NGM:EQL) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 21Is EQL Pharma AB (publ)'s (NGM:EQL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 03What We Learned About EQL Pharma's (NGM:EQL) CEO Compensation
Jan 16
Will the Promising Trends At EQL Pharma (NGM:EQL) Continue?
Dec 28What Type Of Shareholders Make Up EQL Pharma AB (publ)'s (NGM:EQL) Share Registry?
Dec 11EQL Pharma (NGM:EQL) Has Rewarded Shareholders With An Exceptional 436% Total Return On Their Investment
Nov 22AMMINISTRATORE DELEGATO
Axel Schorling (38 yo)
2yrs
Mandato
Mr. Axel Schorling has been Independent Director at Gasporox AB (publ) since 2023. Mr. Schörling is President of EQL Pharma AB (publ) from August 15, 2022. He had been the Chief Operating Officer of EQL Ph...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder & Chairman | 18.6yrs | SEK 1.50m | Nessun dato | |
| President & CEO | 2yrs | Nessun dato | 1.07% SEK 17.1m | |
| Chief Financial Officer | 2.7yrs | Nessun dato | 0.047% SEK 755.1k | |
| Chief Operating Officer | 2yrs | Nessun dato | 0.052% SEK 836.0k | |
| Chief Commercial Officer | no data | Nessun dato | 0.88% SEK 14.1m | |
| Chief Business Development Officer | 1.4yrs | Nessun dato | Nessun dato |
2.0yrs
Durata media
50yo
Età media
Gestione esperta: Il team dirigenziale di EQL è considerato esperto (durata media dell'incarico 2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder & Chairman | 18.6yrs | SEK 1.50m | Nessun dato | |
| Non Independent Director | 9.6yrs | Nessun dato | Nessun dato | |
| Independent Director | 4.6yrs | Nessun dato | 0.0086% SEK 137.5k | |
| Independent Director | 6yrs | Nessun dato | 0.034% SEK 550.0k | |
| Independent Director | 3.6yrs | Nessun dato | 0.034% SEK 550.0k | |
| Independent Director | 3.6yrs | Nessun dato | Nessun dato |
5.3yrs
Durata media
58yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di EQL sono considerati esperti (durata media dell'incarico 5.3 anni).